Phase I/II trial of non-cytotoxic suramin in combination with weekly paclitaxel in metastatic breast cancer treated with prior taxanes (Q36304316)

13 August 2017

Phase I/II trial of non-cytotoxic suramin in combination with weekly paclitaxel in metastatic breast cancer treated with prior taxanes (English)

1 reference

13 August 2017

phase I clinical trial

0 references

cytotoxicity

0 references

phase II clinical trial

0 references

metastatic breast cancer

1 reference

1 reference

1 reference

Maryam B Lustberg

1

1 reference

13 August 2017

Shubham Pant

2

1 reference

13 August 2017

Amy S Ruppert

3

1 reference

13 August 2017

Tong Shen

4

1 reference

13 August 2017

Yong Wei

5

1 reference

13 August 2017

Ling Chen

6

1 reference

13 August 2017

Lisa Brenner

7

1 reference

13 August 2017

Donna Shiels

8

1 reference

13 August 2017

Rhonda R Jensen

9

1 reference

13 August 2017

Michael Berger

10

1 reference

13 August 2017

Ewa Mrozek

11

1 reference

13 August 2017

Bhuvaneswari Ramaswamy

12

1 reference

13 August 2017

Michael Grever

13

1 reference

13 August 2017

Jessie L Au

14

1 reference

13 August 2017

M Guillaume Wientjes

15

1 reference

13 August 2017

Charles L Shapiro

16

1 reference

13 August 2017

language of work or name

1 reference

22 May 2012

1 reference

Cancer Chemotherapy and Pharmacology

13 August 2017

1 reference

13 August 2017

70

1 reference

13 August 2017

1

1 reference

13 August 2017

49-56

1 reference

https://scigraph.springernature.com/pub.10.1007/s00280-012-1887-x

13 August 2017

0 references

cites work

Class III beta-tubulin expression and in vitro resistance to microtubule targeting agents

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3466596

Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3466596

Phase I/II trial of 5-fluorouracil and a noncytotoxic dose level of suramin in patients with metastatic renal cell carcinoma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3466596

Noncytotoxic suramin as a chemosensitizer in patients with advanced non-small-cell lung cancer: a phase II study.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3466596

Quantitative image analysis of intra-tumoral bFGF level as a molecular marker of paclitaxel resistance

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3466596

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3466596

Low-dose suramin enhanced paclitaxel activity in chemotherapy-naive and paclitaxel-pretreated human breast xenograft tumors

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3466596

Fibroblast growth factors: an epigenetic mechanism of broad spectrum resistance to anticancer drugs

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3466596

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3466596

Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3466596

Suramin: a novel antineoplastic agent with multiple potential mechanisms of action

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3466596

Breast cancer molecular subtypes respond differently to preoperative chemotherapy

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3466596

A phase I and pharmacologic study of capecitabine and paclitaxel in breast cancer patients

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3466596

Suramin in combination with 5-fluorouracil (5-FU) and leucovorin (LV) in metastatic colorectal cancer patients resistant to 5-FU+LV-based chemotherapy.

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3466596

Nontoxic suramin as a chemosensitizer in patients: dosing nomogram development.

29 June 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1887-X

A phase I/II study of continuous infusion suramin in patients with hormone-refractory prostate cancer: toxicity and response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1887-X

Suramin in combination with weekly epirubicin for patients with advanced hormone-refractory prostate carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1887-X

Low dose suramin as a chemosensitizer of bladder cancer to mitomycin C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1887-X

Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1887-X

Long-term, weekly one-hour infusion of paclitaxel in patients with metastatic breast cancer: a phase II monoinstitutional study

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3466596

Phase I study of low-dose suramin as a chemosensitizer in patients with advanced non-small cell lung cancer

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3466596

Nontoxic doses of suramin enhance activity of doxorubicin in prostate tumors.

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3466596

Nontoxic doses of suramin enhance activity of paclitaxel against lung metastases

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3466596

Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer an

22 September 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1887-X

Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Patients With Taxane-Resistant Metastatic Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1887-X

Phase II trial of suramin in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

12 December 2020

1 reference

12 December 2020

Suramin in patients with metastatic colorectal cancer pretreated with fluoropyrimidine-based chemotherapy. A phase II study

1 reference

12 December 2020

Suramin is a Potent Inhibitor of Vascular Endothelial Growth Factor. A Contribution to the Molecular Basis of its Antiangiogenic Action

1 reference

12 December 2020

Suramin in non-small cell lung cancer and advanced breast cancer. Two parallel phase II studies

1 reference

12 December 2020

Expression of basic fibroblast growth factor correlates with resistance to paclitaxel in human patient tumors

1 reference

12 December 2020

Phase II trial of capecitabine and weekly paclitaxel as first-line therapy for metastatic breast cancer

1 reference

12 December 2020

Phase II trial of capecitabine and weekly paclitaxel in patients with metastatic breast cancer previously treated with every-3-week taxane therapy

1 reference

12 December 2020

Circulating tumor cells in metastatic breast cancer: biologic staging beyond tumor burden

1 reference

12 December 2020

Microtubule-associated protein-tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptor-positive breast cancer

1 reference

12 December 2020

Pharmacogenetic analysis of paclitaxel transport and metabolism genes in breast cancer

1 reference

12 December 2020

Association of the ABCB1 gene polymorphisms 2677G>T/A and 3435C>T with clinical outcomes of paclitaxel monotherapy in metastatic breast cancer patients

1 reference

12 December 2020

10.1007/S00280-012-1887-X

Identifiers

DOI

1 reference

13 August 2017

1 reference

13 August 2017

1 reference